Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Roche: worldwide collaboration and license agreement (exclusive worldwide rights to RPE cell therapies including OpRegen for ocular disorders); $50.0M upfront, $5.0M milestone received December 2025, tiered double-digit U.S. royalties
Indications
Geographic atrophy (GA) secondary to AMD(Phase 2)
Status note Lead program; allogeneic retinal pigmented epithelial (RPE) cell replacement therapy currently in Phase 2a development (GAlette study ongoing in Israel).
ReSonance
Preclinical · Active
Aliases ANP1
Partnerships William Demant Invest (WDI): research collaboration agreement (August 2025) to advance preclinical development for hearing loss
Indications
Hearing loss (auditory neuropathy)(Preclinical)
Status note Preclinical program for hearing loss; novel deafening model established to support functional preclinical testing under the WDI collaboration.
OPC1
Phase 1 · ActiveModality: cell therapy
Status note Filing references a completed device study at UC San Diego Health in which the novel delivery system successfully administered a one-time injection of OPC1; no indication or trial phase beyond that is stated in the excerpts.
VAC2
Phase 1 · ActiveModality: cell therapy
Partnerships Cancer Research UK (CRUK): clinical trial and option agreement; Lineage exercised early its option to acquire data from the CRUK-conducted Phase 1 trial
Indications
Non-small cell lung cancer(Phase 1)
Status note Phase 1 clinical trial in non-small cell lung cancer being conducted by CRUK.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.